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HPV is currently the most identifiable cause of head and
neck squamous cell cancer (HNSCC). Intriguingly,
although these tumors present at an advanced stage mul-
tiple studies have shown that they are more curable com-
pared to HPV- HNSCC. To better understand why these
more advanced tumors are curable, we have examined the
response to treatment of HPV-positive cancer with radia-
tion and cisplatin.
We have created a syngeneic mouse model of HPV-posi-
tive and HPV-negative HNSCC by transforming mouse
primary tonsil epithelial cells with either HPV oncogenes
or a non-antigenic RNAi strategy that affects similar onco-
genic pathways. Using these transformed cells we exam-
ined the effect of radiation on HPV-positive and HPV-
negative tumors in immune competent and immune
incompetent mice. In addition to the mouse cells we also
examined responses in human cancer cell lines. The
results from our in vitro clonogenic survival assays dem-
onstrate that HPV-positive cells are more resistant to radi-
ation and cisplatin therapy compared to their HPV-
negative counterparts. This result was consistent for
human cancer cell lines, HPV transformed primary tonsil
keratinocytes and HPV transformed mouse primary tonsil
keratinocytes. Surprisingly the reverse sensitivity was
observed in HPV-positive tumors after radiation and cispl-
atin therapy in vivo. HPV tumors were much more sensi-
tive in vivo and at 20 gray of radiation HPV-positive
tumors were eradicated compared to the HPV-negative
counterpart that showed persistent growth. In the same
manner, cisplatin therapy in vivo was able to result in a
cure of HPV-positive tumor but not HPV-negative tumors.
To understand whether an immune response could
explain this enhanced eradication, we repeated the same
studies in syngeneic mice lacking an ability to mount a
cytolytic t-cell response. In these immune incompetent
mice neither radiation nor cisplatin resulted in a cure.
Adoptive transfer of wild-type immune cells into the
immune incompetent mice restored immune clearance
during cisplatin treatment. Our results prove that HPV-
positive tumors are not more curable based on an
increased epithelial sensitivity to cisplatin or radiation
therapy, but rather that these therapies induce a tumor
clearing immune response to this antigenic cancer. The
implications from these results may lead to novel thera-
pies that enhance tumor eradication for HPV-positive can-
cers.
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